Certara Investor Day Presentation Deck
Meeting customers where they are
Hong Kong-based
biotech seeks FDA approval
• Two cancer therapies in
development
Long-time Phoenix customer
Simcyp and drug development
consulting, regulatory writing
and submission support, and
HEOR modeling
Client granted 2 FDA Fast Track
designations
●
●
Nasdaq-traded biotech
needs major regulatory support
Regulatory customer for 6 years
Regulatory writing, including
safety reports and narratives
. NDA and BLA submissions with
GlobalSubmit eCTD publishing
Simcyp and drug development
consulting
Novel cancer drug approved by
FDA in 2021
Top 3 pharma expands
into evidence and access
HS
CI
HN
• 10+ year partnership with
Simcyp, Phoenix, R&D consulting
Expansion with evidence and
access support across
immunology, neuroscience &
oncology programs
o Health economics models, health
technology assessments, payer
insights, dossier, value messaging
Successful coverage achieved in
major and secondary EU markets
73
CERTARAView entire presentation